Last reviewed · How we verify

HMG-CoA Reductase Inhibitor

Seoul National University Hospital · FDA-approved active Small molecule

HMG-CoA Reductase Inhibitor is a HMG-CoA reductase inhibitor (statin) Small molecule drug developed by Seoul National University Hospital. It is currently FDA-approved for Hypercholesterolemia and dyslipidemia, Primary and secondary prevention of cardiovascular disease. Also known as: statin.

HMG-CoA reductase inhibitors block the enzyme that catalyzes the rate-limiting step of cholesterol synthesis, reducing hepatic cholesterol production and lowering blood LDL cholesterol levels.

HMG-CoA reductase inhibitors block the enzyme that catalyzes the rate-limiting step of cholesterol synthesis, reducing hepatic cholesterol production and lowering blood LDL cholesterol levels. Used for Hypercholesterolemia and dyslipidemia, Primary and secondary prevention of cardiovascular disease.

At a glance

Generic nameHMG-CoA Reductase Inhibitor
Also known asstatin
SponsorSeoul National University Hospital
Drug classHMG-CoA reductase inhibitor (statin)
TargetHMG-CoA reductase
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

These drugs competitively inhibit HMG-CoA reductase, the enzyme responsible for converting HMG-CoA to mevalonate in the cholesterol biosynthetic pathway. By reducing intracellular cholesterol levels, they trigger upregulation of LDL receptors on hepatocytes, increasing clearance of LDL from the bloodstream. This class is commonly known as statins and is widely used for cardiovascular risk reduction.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about HMG-CoA Reductase Inhibitor

What is HMG-CoA Reductase Inhibitor?

HMG-CoA Reductase Inhibitor is a HMG-CoA reductase inhibitor (statin) drug developed by Seoul National University Hospital, indicated for Hypercholesterolemia and dyslipidemia, Primary and secondary prevention of cardiovascular disease.

How does HMG-CoA Reductase Inhibitor work?

HMG-CoA reductase inhibitors block the enzyme that catalyzes the rate-limiting step of cholesterol synthesis, reducing hepatic cholesterol production and lowering blood LDL cholesterol levels.

What is HMG-CoA Reductase Inhibitor used for?

HMG-CoA Reductase Inhibitor is indicated for Hypercholesterolemia and dyslipidemia, Primary and secondary prevention of cardiovascular disease.

Who makes HMG-CoA Reductase Inhibitor?

HMG-CoA Reductase Inhibitor is developed and marketed by Seoul National University Hospital (see full Seoul National University Hospital pipeline at /company/seoul-national-university-hospital).

Is HMG-CoA Reductase Inhibitor also known as anything else?

HMG-CoA Reductase Inhibitor is also known as statin.

What drug class is HMG-CoA Reductase Inhibitor in?

HMG-CoA Reductase Inhibitor belongs to the HMG-CoA reductase inhibitor (statin) class. See all HMG-CoA reductase inhibitor (statin) drugs at /class/hmg-coa-reductase-inhibitor-statin.

What development phase is HMG-CoA Reductase Inhibitor in?

HMG-CoA Reductase Inhibitor is FDA-approved (marketed).

What are the side effects of HMG-CoA Reductase Inhibitor?

Common side effects of HMG-CoA Reductase Inhibitor include Myalgia (muscle pain), Elevated liver transaminases, Rhabdomyolysis (rare), Headache, Gastrointestinal upset.

What does HMG-CoA Reductase Inhibitor target?

HMG-CoA Reductase Inhibitor targets HMG-CoA reductase and is a HMG-CoA reductase inhibitor (statin).

Related